Evidence map›Paper›PMID 35239730›Full record

ArticlePloS one2022

Selection of human single domain antibodies (sdAb) against thymidine kinase 1 and their incorporation into sdAb-Fc antibody constructs for potential use in cancer therapy.

Edwin J Velazquez, Jordan D Cress, Tyler B Humpherys, Toni O Mortimer, David M Bellini, Jonathan R Skidmore, Kathryn R Smith, Richard A Robison, Scott K Weber, Kim L O'Neill

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Edwin J VelazquezDepartment of Microbiology and Molecular Biology, Brigham Young University, Provo, UT, United States of America.
Jordan D CressDepartment of Microbiology and Molecular Biology, Brigham Young University, Provo, UT, United States of America.
Tyler B HumpherysDepartment of Microbiology and Molecular Biology, Brigham Young University, Provo, UT, United States of America.
Toni O MortimerDepartment of Microbiology and Molecular Biology, Brigham Young University, Provo, UT, United States of America.
David M BelliniDepartment of Microbiology and Molecular Biology, Brigham Young University, Provo, UT, United States of America.
Jonathan R SkidmoreDepartment of Microbiology and Molecular Biology, Brigham Young University, Provo, UT, United States of America.
Kathryn R SmithDepartment of Microbiology and Molecular Biology, Brigham Young University, Provo, UT, United States of America.
Richard A RobisonDepartment of Microbiology and Molecular Biology, Brigham Young University, Provo, UT, United States of America.
Scott K WeberDepartment of Microbiology and Molecular Biology, Brigham Young University, Provo, UT, United States of America.
Kim L O'NeillDepartment of Microbiology and Molecular Biology, Brigham Young University, Provo, UT, United States of America.ORCID 0000-0002-8747-6217
Brigham Young University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thymidine Kinase 1 (TK1) is primarily known as a cancer biomarker with good prognostic capabilities for both hematological and solid malignancies. However, recent studies targeting TK1 at protein and mRNA levels have shown that TK1 may be useful as a therapeutic target. In order to examine the use of TK1 as a therapeutic target, it is necessary to develop therapeutics specific for it. Single domain antibodies (sdAbs), represent an exciting approach for the development of immunotherapeutics due to their cost-effective production and higher tumor penetration than conventional antibodies. In this study, we isolated sdAb fragments specific to human TK1 from a human sdAb library. A total of 400 sdAbs were screened through 5 rounds of selection by monoclonal phage ELISA. The most sensitive sdAb fragments were selected as candidates for preclinical testing. The sdAb fragments showed specificity for human TK1 in phage ELISA, Western blot analysis and had an estimated limit of detection of 3.9 ng/ml for the antibody fragments 4-H-TK1_A1 and 4-H-TK1_D1. The antibody fragments were successfully expressed and used for detection of membrane associated TK1 (mTK1) through flow cytometry on cancer cells [lung (~95%), colon (~87%), breast (~53%)] and healthy human mononuclear cells (MNC). The most sensitive antibody fragments, 4-H-TK1_A1 and 4-H-TK1_D1 were fused to an engineered IgG1 Fc fragment. When added to cancer cells expressing mTK1 co-cultured with human MNCs, the anti-TK1-sdAb-IgG1_A1 and D1 were able to elicit a significant antibody-dependent cell-mediated cytotoxicity (ADCC) response against lung cancer cells compared to isotype controls (P<0.0267 and P<0.0265, respectively). To our knowledge this is the first time that the isolation and evaluation of human anti-TK1 single domain antibodies using phage display technology has been reported. The antibody fragments isolated here may represent a valuable resource for the detection and the targeting of TK1 on tumor cells.

Indexed as

NeoplasmsSingle-Domain AntibodiesEnzyme-Linked Immunosorbent AssayHumansImmunoglobulin GThymidine KinaseImmunoglobulin GSingle-Domain AntibodiesThymidine Kinasethymidine kinase 1

Identifiers

PMID35239730
PMCPMC8893706
OpenAlexW4221089829

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.